Livongo Health (NASDAQ:LVGO) reached a new 52-week high on Monday . The company traded as high as $81.16 and last traded at $79.88, with a volume of 1290794 shares changing hands. The stock had previously closed at $72.81.
LVGO has been the subject of a number of recent analyst reports. Piper Sandler increased their price target on Livongo Health from $42.00 to $55.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Stifel Nicolaus initiated coverage on Livongo Health in a report on Thursday, March 19th. They set a “buy” rating and a $30.00 price target for the company. Zacks Investment Research downgraded Livongo Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 6th. Goldman Sachs Group downgraded Livongo Health from a “buy” rating to a “neutral” rating and increased their price target for the stock from $48.00 to $70.00 in a report on Thursday, July 2nd. Finally, Canaccord Genuity increased their price target on Livongo Health from $65.00 to $69.00 and gave the stock a “buy” rating in a report on Wednesday, June 3rd. Three equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Livongo Health has an average rating of “Buy” and a consensus price target of $62.71.
The firm has a market cap of $7.59 billion and a P/E ratio of -81.53. The company’s 50-day moving average is $64.75 and its two-hundred day moving average is $39.15.
Livongo Health (NASDAQ:LVGO) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.07. Livongo Health had a negative net margin of 22.05% and a negative return on equity of 11.81%. The business had revenue of $68.80 million for the quarter, compared to analysts’ expectations of $66.11 million. The company’s revenue was up 114.3% on a year-over-year basis. As a group, research analysts forecast that Livongo Health will post -0.37 EPS for the current fiscal year.
In related news, Chairman Glen Tullman sold 170,000 shares of Livongo Health stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $57.44, for a total value of $9,764,800.00. Following the completion of the transaction, the chairman now directly owns 1,071,932 shares in the company, valued at approximately $61,571,774.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Hemant Taneja sold 300,000 shares of Livongo Health stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $52.88, for a total transaction of $15,864,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 515,009 shares of company stock worth $28,872,089. 13.00% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of LVGO. KPCB XVI Associates LLC bought a new stake in shares of Livongo Health during the 4th quarter worth $158,686,000. BlackRock Inc. lifted its holdings in shares of Livongo Health by 181.1% during the 1st quarter. BlackRock Inc. now owns 3,598,006 shares of the company’s stock worth $102,652,000 after acquiring an additional 2,318,002 shares during the last quarter. Matrix Capital Management Company LP bought a new stake in shares of Livongo Health during the 1st quarter worth $21,909,000. Ashford Capital Management Inc. bought a new stake in shares of Livongo Health during the 1st quarter worth $21,276,000. Finally, State Street Corp lifted its holdings in shares of Livongo Health by 257.6% during the 1st quarter. State Street Corp now owns 927,891 shares of the company’s stock worth $26,473,000 after acquiring an additional 668,404 shares during the last quarter. 38.70% of the stock is owned by institutional investors.
Livongo Health Company Profile (NASDAQ:LVGO)
Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.
Further Reading: Marijuana Stocks
Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.